Safety and efficacy of immune checkpoint inhibitors in patients with pre-treatment reduced left ventricular function

Safety and efficacy of immune checkpoint inhibitors in patients with pre-treatment reduced left ventricular function

Abstract Aims Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment outcomes. However, the response varies across different populations, and their use may lead to life-threatening cardiovascular (CV) events. While pre-treatment reduced left ventricular ejection fraction (LVEF) is...

Full description

Saved in:
Bibliographic Details
Main Authors: Maor Tzuberi, Rafael Y. Brzezinski, Nir Flint, Moaad Slieman, Lior Zornitzki, Dana Viskin, Anna Rozenfeld Hemed, Barliz Waissengrin, Renana Barak, Inbal Golomb, Ido Wolf, Netanel Golan, Yan Topilsky, Shmuel Banai, Livia Kapusta, Michal Laufer-Perl
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Cardio-Oncology
Subjects:
LVEF
Immune checkpoint inhibitor
ICIs
Immunotherapy
Cardiotoxicity
Cardio-oncology
Online Access:https://doi.org/10.1186/s40959-024-00297-z
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items